Doc Generici s.r.l.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Doc Generici s.r.l. - overview
Established
1996
Location
Milan, -, Italy
Primary Industry
Pharmaceuticals
About
Doc Generici s. r. l. is an Italian pharmaceutical company that specializes in the production of generic medications, providing cost-effective alternatives for various therapeutic needs while ensuring quality and efficacy for patients.
Founded in 1996 and headquartered in Milan, Italy, Doc Generici s. r. l. focuses on the development and distribution of generic pharmaceuticals.
The company has undertaken five notable deals since its inception, with the most recent deal occurring on October 1, 2023. In its latest funding round, a Secondary Buyout, the company raised EUR 1,100. 00 mn, with investors including Intermediate Capital Group and Merieux Equity Partners. The current CEO is Riccardo Zagaria, who oversees the company’s strategic direction and operational management.
Doc Generici s. r. l. specializes in a comprehensive range of pharmaceutical products, particularly generic medications targeting therapeutic areas such as cardiovascular health, antimicrobial treatments, and pain management solutions.
The company caters to a diverse clientele, including healthcare providers, pharmacies, and institutions across Europe and South America, focusing on delivering affordable yet high-quality options for patients requiring ongoing medical care. For the year 2023, Doc Generici s. r. l.
reported a revenue of EUR 310,777,666. 20, with an EBITDA amount of EUR 126,034,156. 90. The company's revenue model largely relies on B2B transactions, engaging wholesalers and retail pharmacies in bulk sales agreements, supported by competitive pricing strategies to optimize sales volume.
Looking ahead, Doc Generici s. r. l. plans to launch several new products designed to address unmet medical needs, with specific release dates expected in the upcoming quarters.
The company is also targeting expansion into new markets, particularly in North America and Asia, by the end of 2024. The recent funding from the Secondary Buyout will support these initiatives, bolstering research and development efforts and enhancing market entry strategies.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.docgenerici.it
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Doc Generici s.r.l. - timeline of key events
Doc Generici s.r.l. - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 98,872,144 | 115,501,664 | 131,885,123 | 156,626,073 | 162,479,927 | 167,659,022 | 166,474,289 | 179,334,875 | 202,815,167 | 226,810,485 | 235,254,628 | 244,620,805 | - | - | - |
| % Revenue Growth (YoY) | - | 16.8% | 14.2% | 18.8% | 3.7% | 3.2% | (0.7%) | 7.7% | 13.1% | 11.8% | 3.7% | 4.0% | - | - | - |
| EBITDA (USD) | 38,782,113 | 43,235,759 | 44,416,790 | 53,389,342 | 58,355,473 | 60,246,484 | 61,908,462 | 67,023,742 | 80,789,186 | 92,760,121 | 100,663,892 | 106,244,246 | - | - | - |
| Operating Income (USD) | 36,291,734 | 40,291,428 | 41,460,089 | 36,300,128 | 24,375,772 | 26,094,362 | (8,622,556) | 2,588,467 | 16,287,480 | 17,164,852 | 24,998,912 | 30,496,221 | - | - | - |
| Operating Margin | 36.7% | 34.9% | 31.4% | 23.2% | 15.0% | 15.6% | (5.2%) | 1.4% | 8.0% | 7.6% | 10.6% | 12.5% | - | - | - |
| % EBITDA Margin | 39.2% | 37.4% | 33.7% | 34.1% | 35.9% | 35.9% | 37.2% | 37.4% | 39.8% | 40.9% | 42.8% | 43.4% | - | - | - |
| NET Income (USD) | 24,946,801 | 27,606,087 | 28,283,334 | 16,666,281 | 1,089,807 | 6,707,410 | (31,023,626) | (26,777,230) | (16,569,522) | (17,518,726) | (4,872,317) | 40,241,854 | - | - | - |
| % Net Margin | 25.2% | 23.9% | 21.4% | 10.6% | 0.7% | 4.0% | (18.6%) | (14.9%) | (8.2%) | (7.7%) | (2.1%) | 16.5% | - | - | - |
Doc Generici s.r.l. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out | Completed | Bayer AG's Ematonil Plus Emulgel | - | ||||||||
| Add-on, Corporate Carve Out | Completed | Muscoril | - | ||||||||
| Unspecified Exit | Completed | Doc Generici s.r.l. | - | ||||||||
| Secondary Buyout | Completed | Doc Generici s.r.l. | - | ||||||||
| Secondary Buyout | Completed | Doc Generici s.r.l. | - |
Displaying 1 - 5 of 7
Doc Generici s.r.l. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.